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ABSTRACT
Motivation and method: Small-molecule inhibitors targeting the
adenosine triphosphate (ATP) binding pocket of the catalytic domain
of protein kinases have potential to become drugs devoid of (major)
side effects, particularly if they bind selectively. Here, the sequences
of the 518 human kinases are ﬁrst mapped onto the structural
alignment of 116 kinases of known three-dimensional structure. The
multiple structure alignment is then used to encode the known
strategies for developing selective inhibitors into a ﬁngerprint. Finally,
a network analysis is used to partition the kinases into clusters
according to similarity of their ﬁngerprints, i.e. physico-chemical
characteristics of the residues responsible for selective binding.
Results: For each kinase the network analysis reveals the likelihood
to ﬁnd selective inhibitors targeting the ATP binding site. Systematic
guidelines are proposed to develop selective inhibitors. Importantly,
the network analysis suggests that the tyrosine kinase EphB4 has
high selectivity potential, which is consistent with the selectivity
proﬁle of two novel EphB4 inhibitors.
Contact: dhuang@bioc.uzh.ch; caﬂisch@bioc.uzh.ch
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
Protein kinases control and modulate a wide variety of biological
processes through their catalytic activity, which is the transfer of
a phosphate group from adenosine triphosphate (ATP) to other
proteins (Manning et al., 2002). Several among the 518 human
kinases and mutants thereof are causally involved in a large variety
of diseases, and most importantly in cancer (Cohen, 2002; Dibb
et al., 2004; Sawyers, 2004), so that small molecule inhibitors of
pharmacologically relevant kinases have good potential as drug
candidates. Since the ATP binding site is similar in different
kinases, one of the most important challenges in kinase inhibitor
discovery and development is the optimization of selectivity (Traxler
and Furet, 1999), as poor specificity undermines the clinical
effectiveness of some drugs targeting the ATP binding site of protein
kinases (Grunwald et al., 2007; Wolter et al., 2008).
The majority of small-molecule inhibitors of kinases target the
ATP binding site, with the conserved Phe residue of the Asp-Phe-Gly
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(DFG) motif buried in a hydrophobic pocket in the groove between
the two lobes of the kinase (type I inhibitors) (Liu and Gray, 2006;
Pargellis et al., 2002). Another set of inhibitors, so-called type II,
occupy not only the ATP binding site, but exploit also an allosteric
pocket which appears to be accessible only when the Phe side
chain of the DFG motif moves out from the hydrophobic pocket
(Bogoyevitch and Fairlie, 2007; Liu and Gray, 2006; Pargellis et al.,
2002). Type II inhibitors are in general less promiscuous than type
I which is revealed by several selectivity profile data on panels of
kinases ranging from 60 to 318 (Bain et al., 2007; Bamborough
et al., 2008; Fabian et al., 2005; Fedorov et al., 2007; Goldstein
et al., 2008; Karaman et al., 2008). However, some type I inhibitors
can be very specific, e.g. VX-745 and CI-1033 (1 and 2 of Fig. S1,
Supplementary Material) for p38α mitogen-activated protein kinase
(p38α) and epidermal growth factor receptor (EGFR; Karaman
et al., 2008), respectively, and both of them have entered clinical
development. The success of these type I inhibitors demonstrates
that, despite the highly conserved ATP binding site, it is feasible
to optimize selectivity for certain kinases by following appropriate
strategies.
As the majority of kinase inhibitors belong to type I, it is useful
to investigate which kinases have a high likelihood to be inhibited
selectively and if there are systematic guidelines to identify and/or
design selective inhibitors for them. To answer both questions, it is
more useful to compare the key residues of the ATP binding site,
rather than using an overall similarity measure like the percentage
identity of the whole sequence (Hopkins, 2008). Here, first we
accurately identify the ATP binding site residues for most human
kinases via structure and sequence-based approaches. For each
of them, key residues are then selected based on the available
knowledge for developing selective type I inhibitors. These residues
are then encoded into a 9-bit fingerprint and analyzed by a network
approach. The network analysis reveals large differences in the
selectivity potential in the human kinome.
2 METHODS
Structural alignment using the ATP-binding pocket residues The 491
human protein kinase sequences used in this work were taken from the
published data of Manning et al. (2002). The non-redundant PDB structures
of protein kinases with a resolution >3.0 Å have been considered. There
were 116 unique structures (as of May 2008) with ≥95% sequence identity
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to at least one of the 491 human kinase sequences (Manning et al., 2002).
In cases of multiple structures of the same kinase (e.g. with different
inhibitors), the first in chronological order was chosen (see Supplementary
Material for the PDB codes). The Ser/Thr kinase CDK2 (cyclin-dependent
kinase 2, PDB code 1HCK), tyrosine kinase ABL1 (PDB code 1FPU)
and calcium/calmodulin-dependent protein kinase CaMK1a (PDB code
1A06) were arbitrarily selected as templates. Their binding site residues
were identified manually based on the definition shown in Figure 1.
Structural superposition of the other 113 kinases was then performed by
applying a modified version of the Gerstein–Levitt procedure (Gerstein
and Levitt, 1998). To obtain an initial alignment needed for the Gerstein–
Levitt procedure, a sequence alignment algorithm (based on dynamic
programming) was used in which the scoring matrix is a function that
rewards the alignment of Cα pairs with similar local backbone geometry.
After the Gerstein–Levitt alignment step, the list of aligned pairs is purged
by removing pairs (i,j) for which the distance between the Cα atoms in the
structural overlap exceeds a given threshold.
The structural superposition was performed in two steps. First, all Cα
atoms were taken into account to identify the rough binding site residues,
i.e. those within 2 Å of the binding site of CDK2, ABL1 or CaMK1a. Then
the Cα and Cβ atoms of these residues were used to further refine the fitting of
ATP binding sites using a threshold of 3 Å. In addition, fitting mistakes due to
structural variabilities, e.g. crystal packing or conformational changes upon
inhibitor binding, were corrected by comparing with the three templates.
Finally, the residues of the ATP binding site for 116 kinases were identified
and mapped onto the respective kinase sequences.
For other 375 kinases of unknown three-dimensional (3D) structure,
sequence alignments to each of 116 kinase with known structure was
performed using ClustalW v1.8 (Thompson et al., 1994) and BLOSUM30
matrix (Henikoff and Henikoff, 1992). Among them, 239 kinases have
alignment scores >40% of maximal score to at least one of the 116 kinases,
80 kinases have scores between 30% and 40% and the remaining 56 kinases
have scores <30%. The alignment results were checked by visual analysis
of conserved residues (Hanks and Hunter, 1995), e.g. glycine loop, DFG
motif. Finally, the ATP binding sites of 469 kinases were identified and 22
kinases were eliminated from further analysis due to low alignment scores
and missing conserved residues.
Construction of the kinome network based on selective features To
construct the network, each kinase was encoded by a 9-bit string. Every
bit of the string stands for a strategy (Supplementary Material) for designing
selective type I inhibitor and was assigned with an integer value depending
on the corresponding residue. Edges were generated between nodes (kinases)
with difference <3 bits and weighted with 9, 4 and 1 for difference in 0, 1
and 2 bits, respectively. Different weighting schemes change only marginally
the layout of the network but not the clustering into subsets (Supplementary
Material). There are 469 kinases (nodes) and 71 558 edges in the network.
Nodes were colored according to the scheme shown in the bottom and placed
according to the Fruchterman–Reingold algorithm. The figure was made
using igraph (cneurocvs.rmki.kfki.hu).
Enzymatic assay of selectivity profile These experiments were carried out at
the National Centre for Protein Kinase Profiling of University Dundee. All
assays (25.5µl volume) were carried out robotically at room temperature
and were linear with respect to time and enzyme concentration under the
conditions used. Assays were performed for 30 min using Multidrop Micro
reagent dispensers (Thermo Electron Corporation, Waltham, MA, USA) in
a 96-well format. The concentration of magnesium acetate in the assays was
10 mM and [γ-33P]ATP (800 c.p.m./pmol) was used at 5, 20 or 50µM as
indicated in the Supplementary Material, in order to be at or below the Km
for ATP for each enzyme. The assays were initiated with MgATP, stopped
by the addition of 5µl of 0.5 M orthophosphoric acid and spotted on to P81
filter plates using a unifilter harvester (PerkinElmer, Boston, MA, USA).
The data is presented as mean percentage activity at a 3µM concentration
of inhibitor in duplicate assays, and compared with DMSO controls. It has
been reported that percentage activity at single concentration of inhibitor is a
cost-effective proxy of the dissociation constant or the inhibitor concentration
required for half-maximal activity (Bamborough et al., 2008; Lafleur et al.,
2009).
3 RESULTS AND DISCUSSIONS
Structure of the ATP binding site in protein kinases The kinase
catalytic domain is a single polypeptide chain which folds into
two lobes joined by a segment referred as hinge loop (Fig. 1A)
(Hanks and Hunter, 1995). The N-terminal lobe consists of mostly
antiparallel β-sheets and a conserved α-helix, while the C-terminal
lobe is mainly helical (Hanks and Hunter, 1995). ATP binds in a
cavity formed between the two lobes. The ATP binding site is made
up of five pockets (Traxler and Furet, 1999) lined by 36 residues that
are in van der Waals contact and/or involved in hydrogen bond(s)
with one or more inhibitors of type I (Fig. 1).
Several analyses of kinase residues surrounding the ATP binding
site have been published (Chen et al., 2007; Hopkins, 2008;
Sheinerman et al., 2005; Vieth et al., 2004, 2005; Vulpetti and
Bosotti, 2004). The number of 3D structures of kinase domain
deposited in the PDB databank (www.rcsb.org) has increased
substantially in the past 2 years. The growing amount of structural
information calls for a sequence alignment of the human kinome
which should lead to an accurate characterization of the ATP binding
site residues.
Here, it was first verified that in the structural alignment of 116
kinases of known 3D structure the ATP binding site is similar for
different kinases. Then, the binding site residues of 469 kinases
were identified by mapping the sequences of 353 kinases onto the
structural alignment (details are presented in Section 2). Finally,
the residues of the ATP binding site were renumbered from 1 to
36 according to their occurrence along the sequence (Fig. 1B).
Remarkably, the amino acid distribution of the gatekeeper residue
in some of the kinase groups differ significantly from the whole (i.e.
469 kinases) distribution (Fig. 2). In particular, Thr and Phe are much
more frequent among the TK (see legend of Fig. 2 for abbreviations
of kinase groups) and CMGC group, respectively, than in the overall
distribution.
The network of kinase selectivity potential Effective strategies for
the design of selective type I inhibitors mainly consist of targeting
sequence variability at a given position of the ATP binding site
or exploiting a cavity of variable size in different kinases (Liao,
2007; Noble et al., 2004; Traxler and Furet, 1999). These strategies
take into account the gatekeeper residue (Traxler and Furet, 1999),
eventual covalent bonds with cysteine side chains (positions 9, 24
and 33 in Fig. 1B) (Blair et al., 2007; Cohen et al., 1994; Smaill
et al., 2000; Torrance et al., 2000), the hydrogen bonding ability of
the side chain at position 24 (Knight and Shokat, 2005; Laird et al.,
2000; Liao, 2007; Richardson et al., 2006; Swahn et al., 2005), the
intrinsic flexibility of the hinge loop (Fitzgerald et al., 2003; Xing
et al., 2009) and the size of the adenine binding pocket (Liao, 2007).
Nine selectivity features, encoded into nine bits (Fig. 3), are used
here to recapitulate the aforementioned strategies, and each kinase
is then scrutinized for these features. Bit 1 describes the size of
the gatekeeper residue which directly affects the accessibility of the
hydrophobic pocket (Blencke et al., 2003; Eyers et al., 1998; Gorre
et al., 2001; Liu et al., 1999; Shah et al., 1997). About 20% of the
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A
B
C
Fig. 1. 3D structure of the kinase catalytic domain and residues in the ATP
binding site. (A) X-ray crystal structure of ATP bound to cAMP-dependent
protein kinase (PDB code 1ATP). (B) Schematic of ATP binding site and
its five pockets (Traxler and Furet, 1999). (C) 2D projection of the ATP
binding site viewed down the axis from the N-terminal lobe to the C-
terminal lobe. The residues of the ATP binding site are renumbered from
1 to 36 according to their occurrence along the sequence. Red, blue and cyan
circles represent residues which are most (>90%), medium(70–90%) and
not conserved (<70%), respectively. The positions conserved in >70% of the
469 kinases are listed in the right column. [Color figure can be viewed in the
online issue, which is available at http://bioinformatics.oxfordjournals.org.]
A
B
Fig. 2. Amino acid distribution of the gatekeeper residue. (A) The
distribution for 469 protein kinases. (B) The amino acid distribution of
gatekeeper for kinases in different kinase groups. Threonine is most frequent
in TK and TKL. Phenylalanine is most frequent in CMGC. The kinase
groups have been defined as follows (Manning et al., 2002): STE: homologs
of Steriles 7, 11 and 20 kinases; CMGC: CDK, MAPK, GSK3 and
CLK; TK: tyrosine kinase; TKL: tyrosine kinase-like; ACG: PKA, PKG
and PKC; CAMK: calcium/calmodulin-dependent protein kinase; RGC:
receptor guanylate cyclase; CK1: casein kinase 1; others: protein kinases
not belonging to the major groups. [Color figure can be viewed in the online
issue, which is available at http://bioinformatics.oxfordjournals.org.]
human protein kinases have a small gatekeeper, i.e., glycine, valine,
alanine, or threonine. Bit 2 reflects the hydrogen bonding ability
of the gatekeeper. Nearly 20% protein kinases have a gatekeeper
that can act as hydrogen bond donor and/or acceptor (Deininger
and Druker, 2003; Talpaz et al., 2006; Torrance et al., 2000). Bits
3, 4 and 5 report on cysteine at position 9, 24 and 33, respectively.
Around 14, 14 and 10% of kinases have this feature, respectively. Bit
6 describes the hydrogen bonding ability at position 24. Bit 7 relates
to the residue at position 21 in the hinge loop (Fig. 1). In the case of
glycine, backbone conformational changes that lead to differences
in hydrogen bonding patterns with the hinge have been observed
(Fitzgerald et al., 2003). About 10% protein kinases have glycine at
this position. Bits 8 and 9 report on the size of the adenine pocket
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Fig. 3. Definition of 9-bit selectivity fingerprint. Each protein kinase is
encoded by a 9-bit fingerprint based on the strategies for designing selective
type I inhibitors (see text). Every bit stands for a strategy and is assigned with
an integer value. The positions within the 36 residues of the ATP binding
site are listed in Figure 1B. [Color figure can be viewed in the online issue,
which is available at http://bioinformatics.oxfordjournals.org.]
(A-pocket) (Battistutta et al., 2000; Biondi, 2004; Goldsmith et al.,
2007; Liao, 2007; Yde et al., 2005). About 10% protein kinases have
a relatively small adenine pocket. Position 10 (i.e. bit 8) is alanine in
92% of the protein kinases. Note that the aforementioned strategies
for designing selective inhibitors of type I, employed in this work
to derive the 9-bit fingerprint, can be deduced based on sequence
information alone. On the other hand, those strategies that require
the knowledge of the 3D structure (Bikker et al., 2009; Wood et al.,
2004) are not used in this study.
It is useful to consider the 469 kinases (116 and 353 kinases
fitted by structure- and sequence-based alignment, respectively, as
described in Section 2) and the similarity of their 9-bit fingerprints
as nodes and links of a network, respectively (Fig. 4). Interestingly,
kinases belonging to different groups [i.e. widely separated in
the dendrogram of overall sequence similarity (Manning et al.,
2002)] are mixed together upon projection into the plane by a
spring-embedded algorithm (Fruchterman and Reingold, 1991) that
clusters the kinases according to pairwise similarity of the key
residues in the ATP binding site. This result shows that full-sequence
similarity does not correlate with the similarity of the ATP binding
site residues that are relevant for selectivity. In contrast, the 9-bit
fingerprint seems appropriate to determine the selectivity potential.
Particularly, the human kinome is divided into two major sets, A
and B (triangles and circles, respectively, in Fig. 4), depending on
the size of the gatekeeper’s side chain, and each of these two sets
is further partitioned mainly into six clusters and a few outliers.
The most populated cluster belongs to set A and contains the 139
kinases with the most frequent selectivity features. Importantly,
the kinase selectivity potential network is useful for devising
optimization strategies for selective inhibitors. As an example, the
small gatekeeper existing in about 100 kinases of set B, especially
threonine, should be first utilized to gain selectivity over about 400
kinases in set A, and then one could look for other differences to
achieve further selectivity (see below).
Fig. 4. The network of kinase selectivity potential. Pairs of protein kinases
(nodes) are considered to have similar selectivity features (i.e. are connected
by an edge) if they have <3 bits difference in the 9-bit fingerprint of
Figure 3. Edges are weighted quadratically, i.e. with weight 9, 4 and 1
for 0-, 1- and 2-bit difference, respectively. The weighting is used for the
projection onto the plane, which is obtained by a spring-embedder (i.e. force-
directed placement) algorithm (Fruchterman and Reingold, 1991). Similar
projections result by using the same weighting factor for 0-, 1- and 2-
bit difference, or linear weighting (Supplementary Fig. S2). There are 469
kinases and 71 558 edges in this network. The nodes can be divided into
two sets, A (triangles) and B (circles). Set A contains kinases with bulky
gatekeeper residue, whereas set B contains kinases with small gatekeeper.
The fingerprints of the six largest clusters of sets A and B are listed in
the bottom left. Nodes are colored according to the kinase group (Manning
et al., 2002) (scheme shown in the bottom right). Kinases mentioned in
the text are labeled while the kinase name of all nodes can be found in
the Supplementary Material. The variable colors in each cluster show that
full-sequence similarity does not reflect the similarity of key residues in the
ATP binding site. [Color figure can be viewed in the online issue, which is
available at http://bioinformatics.oxfordjournals.org.]
Comparison of the kinase selectivity potential network with
the small molecule–kinase interaction map The usefulness of
the network of kinase selectivity potential can be assessed by
comparing it with the recently published inhibitor profile data
(Karaman et al., 2008) which can also be treated as a complex
network (Fig. 5) (Newwan, 2003). The nodes represent 277 kinases
[upon exclusion of the mutants from the original set of 317
(Karaman et al., 2008)], and the 9394 edges reflect the profile
similarity (PSim) which is a measure of how similarly two kinases
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Fig. 5. The network of kinase inhibitor selectivity. The network is
constructed using PSim which is a pairwise measure of kinase similarity
based on experimentally determined binding affinity values of a set of 24
inhibitors of type I (Karaman et al., 2008). Edges connect pairs of nodes
(kinases) with similar profile of inhibition by the 24 inhibitors. The PSim
weighting is also used for the projection onto the plane by a spring-embedder
algorithm (Fruchterman and Reingold, 1991). The degree of node k is the
number of edges incident to node k, i.e. a measure of how many kinases
share a very similar inhibitory profile as kinase k. The network was plotted
using igraph (cneurocvs.rmki.kfki.hu). [Color figure can be viewed in the
online issue, which is available at http://bioinformatics.oxfordjournals.org.]
interact with a set of 24 type I inhibitors (Karaman et al., 2008).
The value of PSim is calculated for any pair of kinases k1, k2
by PSimk1k2 =
[
1
24
∑24
i=1(Gik1 −Gik2 )2
]− 12
, where Gik is the
affinity of inhibitor i for kinase k, and the index i runs over the
24 inhibitors of type I. Edges are generated between kinases with
PSim ≥ 1/(1.5 kcal/mol), i.e. two kinases are considered similar
and connected by an edge if the root mean square deviation of
their binding free energies for the 24 inhibitors is <1.5 kcal/mol,
corresponding to about 10 times difference in affinity. The number
of edges incident to a given node, so-called degree, indicates the
similarity of a kinase to others with respect to inhibitor profile. Most
kinases are grouped together forming a relatively large cluster and
the remaining ones surround this cluster sparsely (Fig. 5).
To compare with the network of kinase selectivity potential, the
277 kinases are divided into four categories based on their selectivity
fingerprints. Kinases of category 1 are those of cluster 1 in Figure 4.
It is interesting to note that these kinases mostly locate in the center
of the large cluster (Fig. 5) and they have the highest number of edges
(degree). Therefore, kinases of cluster 1 in general have similar
inhibitor profiles, which agrees with the ratiocination of the network
of kinase selectivity potential. The remaining kinases are divided
into three categories according to their similarity to cluster 1 with
respect to the 9-bit selectivity fingerprint. Kinases of categories 2
and 3 differ from category 1 by 1 and 2 bits, respectively. They
mainly locate around the border of the large cluster (Fig. 5) with
average degree of 86 and 72 for categories 2 and 3, respectively. As
they are similar to kinases of category 1, their selectivity potential
against type I inhibitors is expected to be relatively low. The 63
kinases of category 4 (listed in the Supplementary Material) differ
by at least 3 bits compared with those of category 1. They belong
mainly to set B of Figure 4, and locate outside of the large cluster
sparsely (Fig. 5). Their inhibitor profile for the set of 24 inhibitors
is distinct from the majority of the other kinases as indicated by
their average degree of only 33. This observation provides further
evidence on the usefulness of the network analysis based on the
selectivity fingerprint. In other words, the set B kinases, and in
particular the 63 kinases differing by ≥3 bits from cluster 1, have a
fairly high potential to be selective against type I inhibitors.
It is interesting to directly compare the kinase selectivity potential
network and the small molecule–kinase interaction map (Karaman
et al., 2008) for certain specific classes. One interesting case is
CDK2, a kinase belonging to the largest cluster of the selectivity
potential network. Four compounds were developed using CDK2
as the primary target (Karaman et al., 2008). However, these four
compounds are rather promiscuous according to the selectivity score
(relative to their primary target). This result is consistent with the
network analysis which suggests that kinases of the largest cluster
are difficult to be inhibited selectively. On the other hand, the
selectivity potential network is based on nine features and therefore
it may be difficult to explain the selectivity of a specific kinase
inhibitor if it does not fully utilize these features. A typical cases is
p38α. Of the three compounds in advanced development as p38α
inhibitors, only VX-745 is significantly selective, while SB-202190
and SB-203580 are not (Karaman et al., 2008). The main reason is
that the latter two compounds were developed without considering
the selectivity feature concerning the conformational change of the
hinge loop (Fitzgerald et al., 2003).
Usefulness of kinase selectivity potential network: target choice
and strategies to design selective kinase inhibitors The network
classification provides useful information for prioritizing targets
since the selectivity potential can be an important property besides
the pharmaceutical relevance. In general, specific inhibitors are more
likely to be identified for kinases in small clusters and with few links.
One such example is p38α. The unique fingerprints combination
particularly of bits 1, 2 and 7 locates p38α in a cluster of only
three kinases (Fig. 4), and thus very specific type I inhibitors can be
developed by utilizing these features (Fitzgerald et al., 2003; Laufer
et al., 2008; Xing et al., 2009). Another example is Rho-associated
coiled–coiled containing protein kinase (ROCK) which belongs to a
cluster of only 25 kinases (cluster 4). The main hallmark of cluster 4
kinases is the hydrophobic motif (HM) in the adenine binding pocket
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(bit 9). A characteristic phenylalanine residue at the HM can be used
to design selective inhibitors for kinases in this cluster (Jacobs et al.,
2006; Liao, 2007). In contrast, kinases in the large clusters, e.g.
cluster 1, are likely to be recalcitrant to selective inhibition because
a large number of them have similar selectivity features. For these
targets, inhibitor development should follow rules different from
those mentioned above. For instance, targeting allosteric pockets
may be a more appropriate strategy.
The network classification also provides guidelines to develop
selective kinase inhibitors, especially for those kinases in the small
clusters. For example, the eight kinases in group 10 have a threonine
as gatekeeper, and cysteine at position 24. The combination of these
two features is rather unique according to the network analysis.
Therefore, one should try to first make use of these residues, e.g.
forming hydrogen bond to threonine, occupying the hydrophobic
pocket, and also forming a covalent bond to the residue at position
24. In fact, inhibitors having these three features are indeed rather
selective, e.g. CI-1033 (an inhibitor of EGFR, compound 2 in
Supplementary Fig. S1). Similar strategies can be applied for six
kinases in cluster 12, which also have a threonine as gatekeeper and
a cysteine at position 33. Another example is the seven kinases that
are in class 11 and have a valine for gatekeeper and a polar residue at
position 24 which can act as hydrogen bond donor and/or acceptor.
Based on these features, one can design inhibitors that can fully
explore the hydrophobic pocket and also form hydrogen bonds to
the residue at position 24.
Application of kinase selectivity potential: selective inhibitors of
EphB4 The kinases domain of the Ephrin receptor B4 (EphB4)
is an attractive target to develop type I inhibitors as it belongs
to cluster 9, a small cluster of only eight members (Fig. 4). In
2008, Bardelle and coworkers reported a 2,4-bis-anilinopyrimidine
derivative as a remarkably selective inhibitor of EphB4 (Bardelle
et al., 2008). Recently, using high-throughput docking (Kolb et al.,
2008) and hit improvement by medicinal chemistry (Lafleur et al.,
2009), we have discovered the single-digit nanomolar EphB4
inhibitor 10 (see Supplementary Material, Fig. S1). Notably, the
selectivity profile of compound 10 indicates that only 5 of 85
protein kinases are inhibited significantly at 1µM (<20% activity
remained compared with a DMSO control). Three of them belong
to cluster 7 (1 bit different from EphB4), and two of them belong
to cluster 9. Furthermore, compound 11 (Supplementary Material)
is a low micromolar inhibitor of EphB4 discovered in a recent
high-throughput docking campaign (T.Zhou et al., manuscript in
preparation). Its selectivity profile was tested against 85 protein
kinases at a single inhibitor concentration of 10µM. Only for three
kinases <50% activity remained (compared with a DMSO control)
indicating that compound 11 is selective. These results together with
the example of p38α provide evidence that the choice of a kinase
in a small cluster can simplify significantly, or even bypass, the
selectivity optimization process.
Fingerprint extension The current network analysis of selectivity
potential was performed using only nine selectivity features, which
is far from complete. However, a general trend emerges that by
utilizing only a few key descriptors it is feasible to develop selective
inhibitors targeting the ATP binding site for a subset of the kinases.
Note that the profile of inhibition of a subset of kinases belonging
to the same cluster can still be different due to several reasons, e.g.
kinase-dependent binding site flexibility or other selectivity features
not used in the current clustering. The former is usually difficult to
explore but can be used to devise unique strategy for certain kinases,
examples include Lapatinib bound to the C-helix-out from of EGFR
(Bikker et al., 2009; Wood et al., 2004) and JNK3 whose methionine
gatekeeper can be rearranged to allow access to the hydrophobic
pocket (Scapin et al., 2003; Swahn et al., 2005). These features
could be used to extend the fingerprint to obtain a more fine-grained
classification.
4 CONCLUSIONS
The human kinases are aligned based on the primary and tertiary
structures of their ATP binding site. Using this alignment the
strategies for designing selective inhibitors targeting theATP binding
site are encoded in a 9-bit fingerprint. In this way, the kinases and
their ATP binding site similarity can be treated as nodes and links of
a network, respectively. The network analysis reveals the potential
for selective inhibition of each kinase providing useful information
for target prioritization and structure-based drug design. Finally, the
analysis suggests that the tyrosine kinase EphB4 has high selectivity
potential, which is consistent with the selectivity profiles of two
novel inhibitors of EphB4 (compounds 10 and 11 in Supplementary
Fig. S1).
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